124 related articles for article (PubMed ID: 12697729)
1. The fractalkine receptor CX3CR1 is a key mediator of atherogenesis.
Cybulsky MI; Hegele RA
J Clin Invest; 2003 Apr; 111(8):1118-20. PubMed ID: 12697729
[No Abstract] [Full Text] [Related]
2. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis.
Lesnik P; Haskell CA; Charo IF
J Clin Invest; 2003 Feb; 111(3):333-40. PubMed ID: 12569158
[TBL] [Abstract][Full Text] [Related]
3. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK.
Green SR; Han KH; Chen Y; Almazan F; Charo IF; Miller YI; Quehenberger O
J Immunol; 2006 Jun; 176(12):7412-20. PubMed ID: 16751386
[TBL] [Abstract][Full Text] [Related]
4. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts.
Isse K; Harada K; Zen Y; Kamihira T; Shimoda S; Harada M; Nakanuma Y
Hepatology; 2005 Mar; 41(3):506-16. PubMed ID: 15726664
[TBL] [Abstract][Full Text] [Related]
5. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice.
Combadière C; Potteaux S; Gao JL; Esposito B; Casanova S; Lee EJ; Debré P; Tedgui A; Murphy PM; Mallat Z
Circulation; 2003 Feb; 107(7):1009-16. PubMed ID: 12600915
[TBL] [Abstract][Full Text] [Related]
6. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.
Combadiere C; Salzwedel K; Smith ED; Tiffany HL; Berger EA; Murphy PM
J Biol Chem; 1998 Sep; 273(37):23799-804. PubMed ID: 9726990
[TBL] [Abstract][Full Text] [Related]
7. Fractalkine in vascular biology: from basic research to clinical disease.
Umehara H; Bloom ET; Okazaki T; Nagano Y; Yoshie O; Imai T
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):34-40. PubMed ID: 12969992
[TBL] [Abstract][Full Text] [Related]
8. Modulation of atherogenesis by chemokines.
Boisvert WA
Trends Cardiovasc Med; 2004 May; 14(4):161-5. PubMed ID: 15177267
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion.
Harrison JK; Fong AM; Swain PA; Chen S; Yu YR; Salafranca MN; Greenleaf WB; Imai T; Patel DD
J Biol Chem; 2001 Jun; 276(24):21632-41. PubMed ID: 11278650
[TBL] [Abstract][Full Text] [Related]
10. Fractalkine in rheumatoid arthritis and allied conditions.
Umehara H; Tanaka M; Sawaki T; Jin ZX; Huang CR; Dong L; Kawanami T; Karasawa H; Masaki Y; Fukushima T; Hirose Y; Okazaki T
Mod Rheumatol; 2006; 16(3):124-30. PubMed ID: 16767549
[TBL] [Abstract][Full Text] [Related]
11. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans.
McDermott DH; Fong AM; Yang Q; Sechler JM; Cupples LA; Merrell MN; Wilson PW; D'Agostino RB; O'Donnell CJ; Patel DD; Murphy PM
J Clin Invest; 2003 Apr; 111(8):1241-50. PubMed ID: 12697743
[TBL] [Abstract][Full Text] [Related]
12. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions.
Schäfer A; Schulz C; Fraccarollo D; Tas P; Leutke M; Eigenthaler M; Seidl S; Heider P; Ertl G; Massberg S; Bauersachs J
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):55-62. PubMed ID: 17082482
[TBL] [Abstract][Full Text] [Related]
13. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1).
Lucas AD; Bursill C; Guzik TJ; Sadowski J; Channon KM; Greaves DR
Circulation; 2003 Nov; 108(20):2498-504. PubMed ID: 14581400
[TBL] [Abstract][Full Text] [Related]
14. C and CX3C chemokines: cell sources and physiopathological implications.
Stievano L; Piovan E; Amadori A
Crit Rev Immunol; 2004; 24(3):205-28. PubMed ID: 15482255
[TBL] [Abstract][Full Text] [Related]
15. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Damås JK; Boullier A; Waehre T; Smith C; Sandberg WJ; Green S; Aukrust P; Quehenberger O
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2567-72. PubMed ID: 16224053
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype.
Brand S; Hofbauer K; Dambacher J; Schnitzler F; Staudinger T; Pfennig S; Seiderer J; Tillack C; Konrad A; Göke B; Ochsenkühn T; Lohse P
Am J Gastroenterol; 2006 Jan; 101(1):99-106. PubMed ID: 16405540
[TBL] [Abstract][Full Text] [Related]
17. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1.
Mizoue LS; Bazan JF; Johnson EC; Handel TM
Biochemistry; 1999 Feb; 38(5):1402-14. PubMed ID: 9931005
[TBL] [Abstract][Full Text] [Related]
18. [Fractalkine and inflammatory diseases].
Imai T; Nishimura M; Nanki T; Umehara H
Nihon Rinsho Meneki Gakkai Kaishi; 2005 Jun; 28(3):131-9. PubMed ID: 15997176
[TBL] [Abstract][Full Text] [Related]
19. The CX3CL1-CX3CR1 system and psoriasis.
Plant D; Young HS; Watson RE; Worthington J; Griffiths CE
Exp Dermatol; 2006 Nov; 15(11):900-3. PubMed ID: 17002687
[TBL] [Abstract][Full Text] [Related]
20. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue.
Hosokawa Y; Nakanishi T; Yamaguchi D; Nakae H; Matsuo T
Clin Exp Immunol; 2005 Mar; 139(3):506-12. PubMed ID: 15730397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
